- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Sigma-Aldrich announced today the global release of the N-TER(TM) Nanoparticle siRNA Transfection System. N-TER allows researchers to reproducibly interrogate gene function, via siRNA transfection, in model cell types that have previously not been considered amenable to conventional lipid-based siRNA delivery reagents.
"Traditional lipid-based siRNA transfection reagents exhibit a number of drawbacks, including high cell death rates and a limited ability to deliver siRNA into a variety of cell types, such as primary, neuronal, differentiated, and nondividing cells," said Tim Fleming, Director of Global Commercial Marketing at Sigma-Aldrich. "Our goal is to introduce a reagent into the scientific community that effectively bypasses these historic limitations and enables siRNA transfection to be performed in a wider variety of model systems."
The N-TER Nanoparticle siRNA Transfection System circumvents the limitations of lipid-based transfection reagents by relying on a stable nanoparticle, formed by the blending of siRNA and the N-TER peptide, to quickly enter into the cell's cytoplasm to deliver its siRNA cargo.
In addition, due to the reagent's stability, stocks of N-TER/siRNA Nanoparticles can be stored for long periods of time and used for subsequent transfections, increasing standardization and reproducibility in all transfection experiments targeting the same gene.
"Our research on the functions of West Nile Virus proteins involves looking at gene function in a number of different cell types," said Dr. Tom C. Hobman, Professor of Cell Biology at the University of Alberta. "We tested a number of siRNA delivery reagents before using N-TER. Once we tried N-TER, we were very impressed with its ability to reproducibly deliver siRNA into our cell types of interest, with minimal cellular toxicity."
For more information on the N-TER Nanoparticle siRNA Transfection System and to see the list of cell types in which N-TER has been proven to work, please visit http://www.sigma.com/nter .
Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,700 employees providing excellent service worldwide. We are committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning Web site at http://www.sigma-aldrich.com.
Cautionary Statement: This release contains forward-looking statements relating to future strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.
For more information, please click here
St. Louis, MO, USA
Within the USA:
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Feynman Prize Winners Announced! April 26th, 2015
Heat makes electrons’ spin in magnetic superconductors April 26th, 2015